SEC Info - Elanco Animal Health Inc.

SEC Info℠

Home

Help

Please Sign In

Elanco Animal Health Inc. – ‘8-K’ for 8/8/22

On: Monday, 8/8/22, at 7:00am ET · For: 8/8/22 · Accession #: 1104659-22-86903 · File #: 1-38661

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/08/22  Elanco Animal Health Inc.         8-K:2,9     8/08/22   12:558K                                   Toppan Merrill/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     32K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML    279K 
 7: R1          Cover                                               HTML     50K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
 8: XML         XBRL Instance -- tm2222756d1_8k_htm                  XML     19K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 4: EX-101.DEF  XBRL Definitions -- elan-20220808_def                XML     74K 
 5: EX-101.LAB  XBRL Labels -- elan-20220808_lab                     XML    105K 
 6: EX-101.PRE  XBRL Presentations -- elan-20220808_pre              XML     71K 
 3: EX-101.SCH  XBRL Schema -- elan-20220808                         XSD     14K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               27±    35K 
12: ZIP         XBRL Zipped Folder -- 0001104659-22-086903-xbrl      Zip     52K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C: C: C: C:

i 0001739104 i false 0001739104 2022-08-08 2022-08-08 0001739104 us-gaap:CommonStockMember 2022-08-08 2022-08-08 0001739104 elan:TangiblePercentEquityUnitsMember 2022-08-08 2022-08-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): i August 8, 2022

i Elanco Animal Health Incorporated

(Exact name of registrant as specified in its charter)

i Indiana

i 001-38661

i 82-5497352

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer

Identification No.)

i 2500 Innovation Way

i Greenfield, i Indiana

(Address of principal executive offices)

i 46140

(Zip Code)

Registrant’s telephone number, including area code: ( i 877) i 352-6261

Not Applicable

(Former Name or Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

i ¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
i Common stock, no par value	i ELAN	i New York Stock Exchange
i 5.00% Tangible Equity Units	i ELAT	i New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

i ¨ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02

Results of Operation and Financial Condition.

Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated August 8, 2022, announcing the results of operations for the fiscal quarter ended June 30, 2022 and guidance for the full year and third quarter of 2022, for Elanco Animal Health Incorporated.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued by Elanco Animal Health Incorporated, dated August 8, 2022.
104.1		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Elanco Animal Health Incorporated

Date: August 8, 2022	By:	/s/ *Todd Young*
		Name: Todd Young
		Title: Executive Vice President and Chief Financial Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	8/8/22
	6/30/22	4
		List all Filings

↑Top

Filing Submission 0001104659-22-086903 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)